Xiaoyu Zhang Chemical biology and therapeutics

Research Interests

Our research group leverages innovative chemical biology strategies to expand the druggable proteome and develop first-in-class chemical probes for protein targets that remain therapeutically inaccessible. We pursue this mission through three key directions: 1) developing novel chemical tools and technologies to advance targeted protein degradation, 2) designing new chemical modalities to modulate immunological pathways, and 3) developing covalent probes to target extracellular proteinaceous cysteines for functional modulation.

Selected Publications

Exploiting the DCAF16-SPIN4 interaction to identify DCAF16 ligands for PROTAC development. Riha IA, Campos MA, Jin X, Wang FY, Zhang C, Dunne SF, Cravatt BF, Zhang X. RSC Med. Chem., 16 (2025) 892-906.

Discovery of DCAF16 Binders for Targeted Protein Degradation. Campos MA, Riha IA, Zhang C, Mozes C, Scheidt KA, Zhang X. ACS Chem Biol. 2025 Feb 21;20(2):479-488.

Harnessing the FBXW7 somatic mutant R465C for targeted protein degradation. Basu AA, Zhang C, Rouhimoghadam M, Vasudevan A, Reitsma JM, Zhang X. J. Am. Chem. Soc. 2025 Feb 19;147(7):6108-6115.

A platform for mapping reactive cysteines within the immunopeptidome. Zhang C, Zhou C, Magassa A, Jin X, Fang D, Zhang X. Nat Commun. 2024 Nov 8;15(1):9698.

A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation. Basu AA, Zhang C, Riha IA, Magassa A, Campos MA, Caldwell AG, Ko F and Zhang X. Nat. Chem. Bio. 2024 July 04;Online ahead of publication.

A platform for mapping reactive cysteines within the immunopeptidedome. Zhang C, Zhou C, Magassa A, Fang D, and Zhang X. bioRxiv. 2024 April 03;Online ahead of publication.

 

View all publications by Xiaoyu Zhang in the National Library of Medicine (PubMed).